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Abstract 
Background: Considerable differences exist among the living donor Kidney Exchange 
Programmes (KEPs) that are in use and being built in Europe, contributing to a variation in 
the number of living donor transplants [6]. Efforts of European KEPs to exchange (best) 
practices and share approaches to address challenges have, however, been limited. 
Methods: Experts from 23 European countries, collaborating on the ENCKEP COST Action, 
developed a questionnaire to collect detailed information on the functioning of all existing 
KEPs in Europe, as well as their opportunities and challenges. Following a comparative 
analysis, results were synthesised and interpreted by the same experts. 
Results: The practices, opportunities and challenges reported by 17 European countries reveal 
that some of the 10 operating programmes are mature, while others are in earlier stages of 
development. Over 1300 transplants were performed through existing KEPs up to the end of 
2016, providing approximately 8% of their countries‟ living kidney donations in 2015. All 
countries report challenges to either initiating KEPs or increasing volumes. Some challenges 
are shared, whilst others differ because of differences in context (eg, country size, 
effectiveness of deceased donor programme) and ethical and legal considerations (eg, 
regarding living donation as such, nonrelated donors, and altruistic donation). Transnational 
initiatives have started in Central Europe, Scandinavia, and Southern Europe. 
Conclusions: Exchange of best practices and shared advancement of national programmes to 
address existing challenges, aided by transnational exchanges, may substantially improve 
access to the most (cost) effective treatment for the increasing number of patients suffering 
from kidney disease. 
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Introduction 
For patients suffering from end-stage renal disease (ESRD), living donor kidney 
transplantation (LDKT) is more (cost) effective than deceased donor transplantation and 
dialysis ([1], [2], [3]). In particular, it yields better patient and graft survival [4]. Over the past 
2 decades, many countries have developed or intensified LDKT programmes, often to 
supplement shortages in supply of donor organs for deceased donor programmes. Other 
countries however, still largely rely on deceased donor programmes. As of 2015, LDKT 
accumulates to 40% of approximately 80 000 kidney transplantations worldwide [5]. 
The differences in adoption and implementation of LDKT programmes in Europe result in a 
variation from 0 to 33.2 in the number of living donor transplants per million inhabitants per 
year [6]. This variation indicates that initiating and advancing KEPs can bring the benefit of 
treating more European ESRD patients, and/or treating them more (cost)-effectively. 
Originally, LDKT was only feasible for patients with intended living donors of compatible 
blood group and HLA type. Depending on the country, 40% or more of recipients are 
incompatible with their intended donors [5]. Kidney Exchange Programmes (KEPs) enable 
transplantation for recipients who are blood- and/or HLA incompatible with their initially 
intended donors. These incompatible pairs can join a larger pool of recipient-donor pairs, 
within which recipients may exchange donors. The KEP management identifies matching 
donors for the recipients and arranges the transplantations to take place. Many countries 
across the globe, and specifically in Europe, are establishing KEPs and facing a variety of 
common challenges. Additionally, some of the countries with existing KEPs appear to face 
challenges in increasing transplant numbers, despite considerable demand. Hence, there 
appears to be much to gain from collaboration and mutual learning. 
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The COST (Cooperation on Science and Technology) Association funds such a collaboration 
and mutual-learning project, namely the ENCKEP COST Action (European Network for 
Collaboration on Kidney Exchange Programmes [7]).  The COST Association is a European 
framework whose actions are open to all 36 member-states, which is a wider set of countries 
than the EU and includes, eg, Norway and Turkey [9]. In addition, participation is possible 
from Cooperating State Israel, Near Neighbour Countries, and International Partner Countries. 
Hence, we have used a wider definition of Europe in this article, allowing also collaboration 
with and mutual learning from non-European countries. 
ENCKEP started on September 1, 2016, bringing together policy makers, clinicians, and 
optimisation experts from 27 participating countries at the time of writing. The aims of 
ENCKEP are to 1. Exchange best practices and scientific state of the art with respect to 
national KEPs; 2. Develop a jointly-used common framework for data and optimisation; 3. 
Develop and test a prototype for transnational KEPs; 4. Stimulate European policy dialogue 
on this topic. In this study we report on research conducted to achieve the first 
aforementioned aim. We provide a comparative analysis of Europe‟s current KEP practices 
and challenges. 
Materials and methods 
In order to systematically describe current KEP practices in Europe, a questionnaire has been 
developed to identify similarities and differences between countries, and future challenges. 
The questionnaire did not include individual patient or donor data and therefore no ethics 
board approval was needed. 
The questionnaire was based on an earlier questionnaire that had been designed for the 
European Committee on Organ Transplantation within the Council of Europe (CD-P-TO) [8]. 
This original questionnaire was reviewed, amended, and restructured, following expert panel 
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discussion and involving representatives from the participating countries. These discussions 
were conducted partly at the first workshop of the COST Action in January 2017 [7], where 
most of the operating European KEPs were presented, and their main features were identified. 
The detailed written reports of the discussion were subsequently restructured into a new 
questionnaire by a smaller expert group, and then distributed for improvement suggestions to 
ENCKEP participants, resulting in a final commonly-approved questionnaire. The 
questionnaire was divided into sections focusing on: 
- Short country description 
- Numbers of registration and transplantation 
- Activities 
- Challenges and opportunities. 
The questionnaires were sent to representatives of the ENCKEP countries in February 2017, 
who were asked to address all questions applicable to their country by March 2017. The data 
collected through the questionnaires were systematically presented and subsequently 
synthesised into conclusions and recommendations in a workshop in March 2017 [7], by 
representatives of the participating countries, as described in detail in the first ENCKEP 
Handbook [10]. Below, we first present the main results from the questionnaires as viewed 
and prioritised during these workshops. The reflections and interpretations formed during 
these workshops are included in the Discussion and Conclusions. 
Results 
In total, 17 of the 23 countries participating in ENCKEP completed the questionnaire. 
Countries were classified according to the level of development of their KEPs into 4 
categories: 1. large, advanced programmes, 2. smaller operational programmes, 3. 
programmes in preparation, and 4. countries without KEPs (Figure 1). 
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Short country descriptions based on the responses from the questionnaire 
The Netherlands has the highest number of living kidney donations in Europe per million 
population (pmp), and was the first country in Europe to establish a nationally coordinated 
KEP in 2004. The programme is coordinated by the Dutch Transplant Foundation in close 
collaboration with 8 transplant centers and a single Central Reference Laboratory for 
histocompatibility testing. From 2004 through 2016, the Dutch KEP has resulted in 284 
transplants, facilitating exchanges up to 4 pairs 
[11],[12],[13],[14],[15],[16],[17],[18],[19],[20],[21],[22]. The UK Living Kidney Sharing 
Schemes (UKLKSS) includes all 4 nations (England, Wales, Scotland, Northern Ireland) and 
has been operational since 2007. It was made possible by the Human Tissue Acts 2004 
(England, Northern Ireland, and Wales) and 2006 (Scotland). The programme is administered 
by NHS Blood and Transplant (NHSBT) and involves 23 transplant centers and 20 
histocompatibility and immunogenetics (H&I) laboratories. It has become the largest 
operating KEP in Europe, with 250 recipient-donor pairs registered per matching run, and a 
total of 658 transplants reported [23], [24], [25]. The Spanish national programme was 
developed in 2009 by Organización Nacional de Transplantes (ONT) involving 25 of the 39 
transplant centers and 18 H&I laboratories in the country. The Spanish programme is the 
second largest KEP in Europe after the UK with 110 donor-recipient pairs registered per 
matching run, and a total of 147 transplants reported. 
As regards smaller programmes, the Austrian KEP started in 2013 with 4 participating 
transplant centers, coordinated by the Medical University of Vienna, with immunological 
testing on-site [26]. After conducting 11 transplants through 4 2-way exchanges and 1 3-way 
exchange between 2013-2016, Austria joined the Czech Republic to create 1 pool, and the 
first reported transnational exchange was performed in September 2016 [27]. The KEP in the 
Czech Republic started in 2011 and is organised by a single center, the Institute for Clinical 
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and Experimental Medicine (IKEM) Prague. Despite the limited pool size, 60 transplants 
were performed [28]. The reasons for this high number of transplants are: the flexibility in 
performing long exchanges nonsimultaneously (the Czech Republic has conducted 6- and 7-
way exchanges), the fast laboratory testing that facilitates rematching in response to positive 
crossmatch tests, the involvement of altruistic donors and compatible pairs, and the possibility 
of performing ABOi and HLAi transplants after desensitisation within the KEP. The Polish 
programme started in 2015, organised by surgeons from the Department of General and 
Transplant Surgery, Medical University of Warsaw. Five transplants (through 1 2-way and 1 
3-way exchange) had been performed in a single center (Warsaw) by 2016 and the first 
interhospital exchange was performed in 2017 between 2 centers. 
The Belgian Living Donor Exchange Protocol was accepted in 2008 and the national KEP 
started in 2013, organised by the Kidney-Pancreas Committee and the Belgian 
Transplantation Society. The size of the pool is still limited, and 7 transplants have been 
reported through 2 2-way exchanges and 1 3-way exchange. The French KEP started in 2013, 
organised by the Agence de la Biomédecine. A total of 67 patients have been registered with a 
total of 10 transplants performed in 2-way exchanges. Altruistic donation is not legal in 
France, and exchanges involving more than 2 pairs are not yet allowed. The Italian KEP, run 
by the Italian National Transplant Centre (CNT), was established in 2006, but until 2014 only 
single-center exchanges were performed in the Pisa and Siena centers, achieving a total of 15 
transplants. Since 2015 a further 16 transplants were conducted through long, but almost 
simultaneous, altruistic donor chains, involving up to 11 centers. The national KEP in 
Portugal started in 2010, administered by Instituto Português do Sangue e da Transplantação 
(IPST). Five transplant centers out of 8 and 3 H&I laboratories are participating. Fifty patients 
were registered and a total of 9 transplants were reported by the end of 2016. 
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In several countries the KEPs have just been created or are in preparation. Sweden started its 
national KEP in 2016. In 2017, the initiative was taken up by Scandiatransplant, under the 
name of ScandiaTransplant Kidney Exchange Program (STEP), involving Sweden, Denmark 
and Norway. A matching policy has been agreed and 2-way exchanges are currently allowed 
[29]. However, no transplants have been performed yet. In Switzerland, kidney exchange has 
been regulated by the Swiss Transplantation Law since 2007, but only a few ad hoc 2- and 3-
way exchanges have been performed so far. In fact, in 1999, Europe‟s first kidney exchange 
was carried out in Switzerland. However, there were legislative and organizational 
restrictions. Since these are solved, the Swiss KEP is expected to start in 2018 [30]. In 
Greece, a national KEP will be established by the Hellenic Transplant Organisation (EOM) in 
the near future, involving 5 kidney transplant centers. There is no national KEP in Slovakia 
yet, but there have been 7 ad hoc 2-way exchanges between 2005-2015. Among those, 6 were 
performed in single centers (within 3 of the 4 transplant centers in Slovakia) and 1 exchange 
was between 2 centers. 
We have no information on other operating KEPs in Europe. However, Romania had a single 
center KEP in Cluj-Napoca from 2001 [31], [32]. Between 2001 and 2005, their medical team 
performed 56 transplants through 23 2-way exchanges, 2 3-way exchanges and 1 4-way 
exchange. 
Regarding the countries that provided responses to our survey, but had no KEPs, Finland and 
Iceland are part of Scandiatransplant but they do not participate in STEP yet. Kidney 
exchange is not legally allowed in Finland; the Helsinki center performs all LDKT in the 
country. The LDKT programme in Iceland is supported by a visiting surgeon from the USA, 
and patients travel to Sweden for a deceased donor kidney transplant (DDKT). Recipient-
donor pairs of Ireland can register through a UK transplant center for entry into UKLKSS, 
altogether 6 transplants have been performed by that route. 
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Statistics and comparisons 
Regarding 12-month performance, the number of registrations and the number of 
transplantations conducted in 2015 can be seen in Figure 2. 
The active KEPs in all 10 countries listed are organised centrally, although in the Czech 
Republic and Poland the programmes initially operated in the capitals, but they are now 
enlarging. Regarding legal restrictions, altruistic donation is not possible in France, Poland, 
Greece and Switzerland. In France and Portugal, only incompatible pairs can participate in the 
KEP. In France, only 2-way exchanges are possible. In principle, nonresident donor-recipient 
pairs can be involved in the majority of the KEPs except Portugal, where only resident 
recipients can join the KEP, and Belgium, where the recipient must be resident in a 
Eurotransplant country. Anonymity is a legal requirement in most countries and it is part of 
the protocol in all countries, except Poland. Compatible pairs can participate in KEPs in the 
advanced programmes. In Spain, both paediatric recipients and compatible pairs are 
prioritised within the KEP. Usually organs travel rather than donors, except in the 
Netherlands, Slovakia and Switzerland, where the donors travel according to the protocol. 
Simultaneous surgeries for exchanges are required everywhere by protocol, except in the 
Czech Republic and Poland due to large exchanges and lack of operating theatres, 
respectively. 
In most countries, there are national guidelines for donors and recipients to enter the KEP. All 
the donors and recipients are fully assessed before inclusion in a KEP and in some countries 
special rules apply for clinically complex donors. Usually large countries have multiple 
laboratories to carry out crossmatch testing and smaller countries use 1 laboratory only. In all 
of the KEPs the exchanges/chains are identified after a virtual crossmatch and then these are 
confirmed in a laboratory crossmatch. Most countries have nationally agreed definitions of 
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HLA incompatibility and a commonly used Mean Fluorescence Intensity MFI threshold 
(between 2000-3000). Almost all countries consider results from historical samples as well, 
but the current ones are deemed most relevant. The practice regarding formal arrangements 
for reimbursing the expenses and loss of earnings of living donors varies between countries, 
but the countries with the most advanced KEPs have cost neutral reimbursement policies. 
The algorithms which match recipients with donors mostly aim to maximise the number of 
transplants, in combination with a variety of other criteria. In many countries the optimisation 
considers the HLA-match between donors and recipients and/or blood type compatibility.  
Blood type identical transplants can be prioritised. Additionally, algorithms might look for 
smaller donor-recipient age-differences and travel distances (coming from the same region). 
In the UK donor-donor age difference is used as a tie-breaker between possible matches. The 
sensitisation and the waiting time of the patient can also matter. Shorter exchange cycles are 
generally preferred in the solution. 
We summarise these and other main features of the European KEPs in Table 1. We also 
included general data on the transplant activity of the countries covered in our survey in Table 
2 and Table 3. 
Overview of activity beyond Europe 
There are several countries outside Europe where KEPs are operational, eg, in South Korea, 
USA, Canada, and Australia. For further information, we refer to 2 recent surveys [24,25] on 
KEPs around the world. Here, we include a description of the situation in the USA, and 
information on one of their nationwide KEPs, ie, the United Network for Organ Sharing 
(UNOS), which was established in 2010. UNOS is a partner organization in the ENCKEP 
COST Action. 
AC
CE
PT
ED
14 
 
In the USA, UNOS (which administers the Organ Procurement and Transplantation Network 
(OPTN)), the National Kidney Registry (NKR) and the Alliance for Paired Donation (APD) 
are the 3 KEPs operating nationwide. In addition, many regional and single-center 
programmes exist within approximately 250 living donor transplant centers. Seventy centers 
are actively participating with UNOS from among the 160 centers registered with this 
organization. Of note is that approximately 200 centers have conducted at least 1 transplant in 
an exchange through an internal hospital programme, a regional programme, or one of the 
national programmes in the USA. Some of the large transplant centers perform the majority of 
their exchanges in-house and report only their hard-to match patient-donor pairs to the 
national programmes. One of the organizational implications of this fragmented system is that 
the national KEPs do not wait to build up their pools, as is common practice in Europe. 
UNOS conducts matching runs every week, and NKR and APD search for exchanges 
immediately after each registration. UNOS allows 2- and 3-way exchanges and 4-way chains 
for logistical reasons. Among the 173 transplants performed between 2010-2015, 52 were 
through 2-way exchanges 75 through 3-ways and 46 through altruistic chains. The high (90%) 
failure rate is the main issue in the US system. By the end of 2015, UNOS had 1628 
registered patients and they identified 2246 matches in virtual crossmatch tests. Only 173 
transplants proceeded, which is partly due to the practice of centers registering only hard-to-
match patients and the lack of consistency in the HLA-lab testing. 
Challenges and opportunities 
The survey identified the following main challenges for countries that do not yet operate a 
KEP: (i) lack of knowledge about KEPs; (ii) lack of software tools; (iii) lack of a legal 
framework; and (iv) the small size of the country. 
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Descriptions of existing practices, as for instance provided above, as well as the ENCKEP 
COST Action itself, improve access to information and knowledge and serve to address the 
first challenge. Software to manage and optimise KEPs will also be investigated by ENCKEP, 
and future reports will enhance accessibility of existing technology for new countries. 
The development of legislation to allow kidney exchanges (and its new modalities) is a task 
for policy makers and governments, in alignment with public opinion about living donor 
organ donation. Being well-informed about the operation and effects of existing KEPs across 
Europe may influence the beliefs and opinions of medical professionals, policy makers, the 
public and the government. Finally, as to the size of the country being a limitation, our results 
show that some medium-sized countries run effective KEPs or engage in international 
cooperation to this purpose. 
Regarding the countries with operating KEPs, a key challenge reported by all countries is to 
maintain or increase the KEP pool size by encouraging new registrations. This holds 
particularly true for HLAi or ABOi pairs when routinely referred for desensitisation treatment 
(as is for example the case in France, Italy, and Sweden).  The accumulation of highly HLA 
sensitised recipients in the pool is an issue for several countries, making it difficult to find 
suitable matches for immunologically complex recipients. As an example, we note that in 
Spain the proportion of highly sensitised (PRA>75%) patients has gradually increased from 
around 20% in 2010 to 50% in 2015. 
There are essentially 3 categories of opportunities to improve the performance of the KEPs: 
(i) extending the national pools, (ii) allowing new modalities in the exchange, and (iii) 
increasing international cooperation. 
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(i) Extending national pools 
 Reaching full coverage in the national KEPs through the participation of all the 
transplant centers. 
 Inclusion of compatible pairs to achieve better HLA or age match for the recipients 
involved and generating more exchange opportunities for other recipients. 
 Inclusion of HLA incompatible pairs in preference to antibody removal, and inclusion 
of ABO incompatible pairs to avoid the costs and higher risks associated with 
desensitisation programmes (at least by registering them for a number of runs in the 
KEP before choosing these alternative treatments). 
 Inclusion of altruistic (unspecified) donors to trigger KEP chains, where the 
transplants can be nonsimultaneous and in the form of long or „never ending‟ chains. 
 Allowing multiple potential donors to register for 1 patient to improve the chances of 
identifying exchange cycles. 
(ii) Allowing new modalities in the exchange 
 Extending the length of simultaneous exchange cycles and nonsimultaneous chains. 
 Considering HLAi and ABOi transplantations for hyperimmunised patients, in order 
for them to receive a kidney that is immunologically better than his/her original 
donor's, with the help of desensitisation treatment. 
 Improving the effectiveness of the selection of exchanges by fine-tuning the 
interaction between optimisation and the virtual and laboratory crossmatch tests. 
Flexibility with finding alternative exchanges in the light of a positive crossmatch is 
important in order to maximise transplants. 
 Establishing an optimal run frequency. Depending upon the dynamics of the pool, 
finding the right frequency may further enhance the performance of the KEP. 
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(iii) Increasing international cooperation 
There are a number of different models for current international collaborations and plans: 
some are led by an advanced KEP, whilst other countries are joining together their small 
pools in order to create larger pools. In the UK, patient-donor pairs from Ireland are welcome 
to participate, and 6 recipients have already received transplants. Spain, with the second 
largest KEP in Europe, has started cooperation with Italy and Portugal. The Netherlands 
helped to establish the Belgian KEP by sharing their software. France and Switzerland signed 
a KEPs convention in 2015, but to date no run has succeeded in identifying matched pairs. 
France is also in negotiation with Belgium. Austria and the Czech Republic have already 
joined their pools and performed their first transnational exchange in September 2016 [27], 
followed by a 3-way kidney exchange on 5th December 2017 involving 2 pairs in Prague and 
1 in Vienna. Based on the Swedish initiative, Scandiatransplant has just started the 
coordination of a joint KEP involving Denmark, Norway, and Sweden. Eurotransplant is 
helping with the organization of the Belgian KEP and, theoretically, it is possible for a 
resident of a Eurotransplant country to join a KEP in another Eurotransplant country. 
International Collaboration is an opportunity that in turn poses new challenges. It requires 
many legislative, medical, financial, and ethical issues to be resolved. As the example of 
deceased organ sharing networks (such as Eurotransplant and Scandiatransplant) shows, such 
international cooperation is feasible and can be beneficial for all stakeholders, and especially 
the highly sensitised patients. 
Discussion 
This study provides a comprehensive review of the state of the art of European KEPs in living 
donor kidney transplantation, identifying their key characteristics and their main challenges. 
Our findings clearly reveal the complexity of the (interorganizational) structures and 
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processes involved in KEPs. It appears that there is a considerable diversity among KEPs in 
participating countries, each having been developed in a different context and taking its own 
approach to address country-specific challenges. The most advanced programmes with a 
longer history have experience of how to advance by continuous review and improvement. 
The emerging/developing programmes can learn from these advancements as well as from 
other early stage programmes to develop a model that is suitable for their requirements. 
Recognising the differences in ethical viewpoints, legal frameworks, clinical practices, 
geography, population size, et cetera, it is clear that solutions that appear to work best in one 
country may be suboptimal in another and vice versa. One „model‟ does not fit all. 
The same differences between systems imply that collaboration in the form of transnational 
KEPs adds new complexities regarding ethical, legal, clinical, and financial frameworks of the 
countries involved. New principles, conditions and objectives are called for to ensure that 
collaboration appropriately benefits all populations, recipients and donors involved. Such 
collaboration may particularly benefit the growing number of highly sensitised patients who 
are hard to match nationally. 
Recommendations for national KEPs 
Based on our study we have identified the following key characteristics that define KEP 
effectiveness: 
 a transparent, objective, and responsible donor selection system, including both 
physical and psychological screening; 
 consistent and responsive systems and processes including matching software, 
immunological testing, organizational framework, and central coordination; 
 clinical leadership to establish confidence in the KEP as the treatment of choice for 
immunologically complex recipients and compatible recipient-donor pairs seeking a 
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better age or HLA match and to ensure that recipients and donors are appropriately 
informed about their treatment options; 
 recipient and donor awareness to inform their decision-making and encourage 
participation in the KEP; 
 a centralised follow up system, to monitor the effectiveness of the programme in terms 
of the impact on the donor and recipient, and more generally in terms of overall 
outcomes; 
 a culture of continuous improvement to develop the KEP in response to innovations in 
the field, clinician, and patient choice, and to actively manage potential risks (eg, 
diminishing pool size, nonproceeding transplants, low uptake of the KEP). 
 
Future work 
Based on the trends observed in the development of European KEPs, we expect that new 
national programmes to be established and that countries with operating KEPs will advance 
their programmes according to the opportunities described above. In particular, we believe 
that more countries will permit altruistic donors to trigger long chains as part of the proposed 
exchanges, more countries will allow the participation of compatible donors in the 
programmes by providing quality guarantees for these patients, and desensitisation treatment 
will be better coordinated with the KEPs. 
Besides the improvement of the national programmes, we expect the ongoing international 
collaborations to extend rapidly, partly facilitated by our ENCKEP COST Action, in 
particular for: 
 sharing knowledge and expertise to support new, emerging, and developing 
programmes; 
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 effective cross-border collaborations to improve pool size and optimisation; 
 advanced cross-border schemes to maximise options for immunologically complex 
recipients who remain unmatched within their own country KEPs. 
Our ENCKEP network continues to conduct scientific research in an international and 
interdisciplinary collaboration on KEPs. The next steps are to identify best practices in 
modelling and optimisation aspects of the KEPs, and to address the ethical and legal 
challenges of (inter)national KEPs. 
As effective KEPs ultimately benefit all patients, we hope that the presented detailed 
description of current KEP practices will guide advances in practice, foster international 
cooperation, and promote access to transplantation for the growing population of ESRD 
patients. 
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FIGURE LEGENDS 
Figure 1: Development of KEPs by country 
 
Figure 2: KEP activity: number of proceeding transplants and the number of new recipients 
registered in 2015 by country. 
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Figure 2 
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Table 1: Summary of the characteristics of European kidney exchange programmes. The first 
10 countries have operating programmes and the last 2 countries will start their KEPs in 2018. 
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Matching 
process 
every x 
months 
(NR=not 
regular) 
NR NR 3 3 NR 3 1 3 4 3 na 3 
Longest 
exchange 
already 
conducted 
3 3 7 2 2 4 3 3 3 3 na na 
Longest 
chain already 
conducted 
na na 6 na 6 3 na na 6 3 na na 
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Table 2: General information about the kidney transplantation activities of the 17 countries 
covered in the survey for 2016 from Newsletter Transplants [6], except the information 
denoted by * and ** that were not included in [6], so we took them from our survey provided 
for years 2015 (*) and 2016 (**), respectively, (here “nd” means we had no data provided 
from either of the 2 sources). Part a) countries with operating KEPs.  
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Table 3: General information about the kidney transplantation activities of the 17 countries 
covered in the survey for 2016 from Newsletter Transplants [6] , except the information 
denoted by * and ** that were not included in [6], so we took them from our survey provided 
for years 2015 (*) and 2016 (**), respectively, (here “nd” means we had no data provided 
from either of the 2 sources). Part b) countries with no operating KEP yet. 
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